Steve Eppler
YOU?
Author Swipe
View article: Data from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Data from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Open
Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the receptor tyrosine kinase MET.Experimental Design: This 3+3 dose-escalation …
View article: Supplementary Methods, Tables 1 - 2 from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Supplementary Methods, Tables 1 - 2 from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Open
PDF file - 88K, Table S1. Treatment-related adverse events across all dosing cohorts in Phase Ia escalation and expansion, and Phase Ib. Table S2. Most commonly reported adverse events regardless of relationship to study drug.
View article: Data from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Data from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Open
Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the receptor tyrosine kinase MET.Experimental Design: This 3+3 dose-escalation …
View article: Supplementary Methods, Tables 1 - 2 from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Supplementary Methods, Tables 1 - 2 from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Open
PDF file - 88K, Table S1. Treatment-related adverse events across all dosing cohorts in Phase Ia escalation and expansion, and Phase Ib. Table S2. Most commonly reported adverse events regardless of relationship to study drug.